DAVID J STROBL
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
- Where
- LANSING, MI
- NPI
- 1861490658
- Received
- $444,677 in 540 records, 2019 to 2025
- As principal investigator
- $501,194 of research payments to others in 199 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 23 | $19,235 |
| 2024 | General payment | 34 | $25,343 |
| 2023 | General payment | 25 | $18,684 |
| 2022 | General payment | 30 | $46,405 |
| 2021 | General payment | 29 | $35,578 |
| 2020 | General payment | 120 | $84,710 |
| 2019 | General payment | 279 | $214,719 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Amgen Inc. | 236 | $185,056 | 2019–2025 |
| Amarin Pharma, Inc. | 206 | $161,412 | 2019–2025 |
| SANOFI-AVENTIS U.S. LLC | 52 | $40,086 | 2019 |
| Esperion Therapeutics, Inc. | 24 | $29,123 | 2020–2022 |
| Kowa Pharmaceuticals America, Inc. | 3 | $22,615 | 2019 |
| Regeneron Healthcare Solutions, Inc. | 16 | $6,330 | 2019 |
| Regeneron Pharmaceuticals, Inc. | 1 | $26 | 2019 |
| Alexion Pharmaceuticals, Inc. | 1 | $13 | 2019 |
| GlaxoSmithKline, LLC. | 1 | $12 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 159 | $379,799 |
| Consulting Fee | 4 | $35,610 |
| Travel and Lodging | 205 | $19,472 |
| Food and Beverage | 171 | $9,744 |
| Education | 1 | $51 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-04-22 | Amarin Pharma, Inc. | $3,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, cardiovascular | 2025 | |
| 2025-04-22 | Amarin Pharma, Inc. | $1,740 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, cardiovascular | 2025 | |
| 2025-04-10 | Amarin Pharma, Inc. | $92 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, cardiovascular | 2025 | |
| 2025-04-10 | Amarin Pharma, Inc. | $89 | Food and Beverage | In-kind items and services | Vascepa Drug, cardiovascular | 2025 | |
| 2025-04-09 | Amgen Inc. | $20 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-04-09 | Amgen Inc. | $16 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-04-02 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-04-02 | Amgen Inc. | $105 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-04-02 | Amgen Inc. | $50 | Food and Beverage | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-04-02 | Amgen Inc. | $20 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-27 | Amgen Inc. | $97 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-26 | Amgen Inc. | $182 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-26 | Amgen Inc. | $23 | Food and Beverage | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-26 | Amgen Inc. | $10 | Travel and Lodging | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-25 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-25 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-18 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-18 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-13 | Amgen Inc. | $775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-12 | Amgen Inc. | $124 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-11 | Amgen Inc. | $86 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-02-19 | Amarin Pharma, Inc. | $1,740 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, cardiovascular | 2025 | |
| 2025-01-09 | Amgen Inc. | $88 | Food and Beverage | In-kind items and services | 2025 | ||
| 2024-12-03 | Amgen Inc. | $100 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-12-03 | Amgen Inc. | $22 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-12-03 | Amgen Inc. | $20 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-09-17 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-09-17 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-09-11 | Amgen Inc. | $124 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-07-16 | Amarin Pharma, Inc. | $3,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, cardiovascular | 2024 | |
| 2024-07-10 | Amarin Pharma, Inc. | $115 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, cardiovascular | 2024 | |
| 2024-07-10 | Amarin Pharma, Inc. | $90 | Food and Beverage | In-kind items and services | Vascepa Drug, cardiovascular | 2024 | |
| 2024-07-10 | Amarin Pharma, Inc. | $20 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, cardiovascular | 2024 | |
| 2024-05-30 | Amgen Inc. | $109 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-05-30 | Amgen Inc. | $104 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-05-30 | Amgen Inc. | $23 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-05-30 | Amgen Inc. | $22 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-05-30 | Amgen Inc. | $20 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-05-30 | Amgen Inc. | $20 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-05-23 | Amgen Inc. | $2,325 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-05-22 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-05-22 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-05-15 | Amgen Inc. | $124 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-05-08 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-05-08 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-04-30 | Amgen Inc. | $20 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-04-30 | Amgen Inc. | $18 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-04-30 | Amgen Inc. | $12 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-04-25 | Amgen Inc. | $20 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-04-25 | Amgen Inc. | $15 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-04-25 | Amgen Inc. | $12 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-04-24 | Amgen Inc. | $96 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-04-16 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-04-10 | Amgen Inc. | $111 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-03-04 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2024 | |
| 2024-02-28 | Amgen Inc. | $103 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-02-21 | Amarin Pharma, Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, cardiovascular | 2024 | |
| 2023-12-12 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-12-12 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-12-07 | Amgen Inc. | $124 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-11-23 | Amgen Inc. | $20 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-11-23 | Amgen Inc. | $15 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-11-23 | Amgen Inc. | $11 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-11-22 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-11-16 | Amgen Inc. | $98 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-10-25 | Amgen Inc. | $20 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-10-25 | Amgen Inc. | $15 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-10-25 | Amgen Inc. | $12 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-10-09 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-10-03 | Amgen Inc. | $76 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-08-29 | Amgen Inc. | $104 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-08-29 | Amgen Inc. | $20 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-08-29 | Amgen Inc. | $15 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-08-28 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-08-28 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-08-23 | Amgen Inc. | $77 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-07-10 | Amgen Inc. | $196 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-07-10 | Amgen Inc. | $40 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-07-10 | Amgen Inc. | $10 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-07-03 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-07-03 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2023-03-24 | Amgen Inc. | $775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2023 | |
| 2022-12-30 | Amgen Inc. | $168 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-12-30 | Amgen Inc. | $162 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-12-30 | Amgen Inc. | $19 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-12-30 | Amgen Inc. | $15 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-12-30 | Amgen Inc. | $12 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-12-22 | Amarin Pharma, Inc. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2022 | |
| 2022-12-20 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-12-20 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-12-15 | Amgen Inc. | $83 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2022 | |
| 2022-12-02 | Amgen Inc. | $775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-11-29 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-11-29 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-11-28 | Amgen Inc. | $97 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-11-28 | Amgen Inc. | $23 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-11-28 | Amgen Inc. | $22 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-11-21 | Amgen Inc. | $76 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2022 | |
| 2022-11-15 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-11-15 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-11-10 | Amgen Inc. | $113 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2022 | |
| 2022-09-16 | Amgen Inc. | $102 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-09-16 | Amgen Inc. | $25 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-09-09 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-09-09 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-05-23 | Amgen Inc. | $12,500 | Consulting Fee | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-05-23 | Amgen Inc. | $500 | Consulting Fee | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-05-19 | Amarin Pharma, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2022 | |
| 2022-05-05 | Amgen Inc. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-03-18 | Amarin Pharma, Inc. | $10,660 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2022 | |
| 2022-02-16 | Esperion Therapeutics, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2022 | |
| 2022-01-20 | Amarin Pharma, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2022 | |
| 2021-11-30 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2021 | |
| 2021-11-15 | Amgen Inc. | $120 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2021 | |
| 2021-09-22 | Esperion Therapeutics, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-09-08 | Esperion Therapeutics, Inc. | $2,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-09-01 | Amgen Inc. | $193 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2021 | |
| 2021-09-01 | Amgen Inc. | $25 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2021 | |
| 2021-09-01 | Amgen Inc. | $20 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2021 | |
| 2021-08-31 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2021 | |
| 2021-08-31 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2021 | |
| 2021-08-31 | Esperion Therapeutics, Inc. | $84 | Food and Beverage | In-kind items and services | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-08-06 | Amgen Inc. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2021 | |
| 2021-07-27 | Esperion Therapeutics, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-07-21 | Esperion Therapeutics, Inc. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-07-14 | Esperion Therapeutics, Inc. | $2,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-07-08 | Esperion Therapeutics, Inc. | $104 | Food and Beverage | In-kind items and services | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-07-08 | Esperion Therapeutics, Inc. | $97 | Travel and Lodging | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-07-08 | Esperion Therapeutics, Inc. | $15 | Food and Beverage | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-07-07 | Esperion Therapeutics, Inc. | $2,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-06-29 | Esperion Therapeutics, Inc. | $90 | Food and Beverage | In-kind items and services | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-06-24 | Amarin Pharma, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-06-23 | Esperion Therapeutics, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-06-02 | Amarin Pharma, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-05-21 | Amgen Inc. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2021 | |
| 2021-05-13 | Amarin Pharma, Inc. | $1,560 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-05-12 | Esperion Therapeutics, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-05-05 | Amgen Inc. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2021 | |
| 2021-04-07 | Esperion Therapeutics, Inc. | $1,980 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2021-03-24 | Amarin Pharma, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2021 | |
| 2021-03-10 | Esperion Therapeutics, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2021 | |
| 2020-12-03 | Amarin Pharma, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-11-24 | Esperion Therapeutics, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2020 | |
| 2020-11-04 | Esperion Therapeutics, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2020 | |
| 2020-10-30 | Amgen Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-10-28 | Esperion Therapeutics, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2020 | |
| 2020-10-21 | Esperion Therapeutics, Inc. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2020 | |
| 2020-10-19 | Amgen Inc. | $1,034 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-10-09 | Esperion Therapeutics, Inc. | $51 | Education | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2020 | |
| 2020-10-07 | Esperion Therapeutics, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2020 | |
| 2020-10-05 | Amgen Inc. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-09-30 | Esperion Therapeutics, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2020 | |
| 2020-09-30 | Esperion Therapeutics, Inc. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEXLIZET Drug, ANTILIPEMIC AGENTS | 2020 | |
| 2020-09-23 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2020 | |
| 2020-08-31 | Amgen Inc. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-07-27 | Amarin Pharma, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-07-13 | Amarin Pharma, Inc. | $875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-04-20 | Amarin Pharma, Inc. | $6,240 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-04-08 | Amarin Pharma, Inc. | $4,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-04-06 | Amarin Pharma, Inc. | $349 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-04-06 | Amarin Pharma, Inc. | $106 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-04-06 | Amarin Pharma, Inc. | $72 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-04-06 | Amarin Pharma, Inc. | $24 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-25 | Amarin Pharma, Inc. | $125 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-25 | Amarin Pharma, Inc. | $110 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-25 | Amarin Pharma, Inc. | $10 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-25 | Amarin Pharma, Inc. | $10 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-25 | Amarin Pharma, Inc. | $10 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-25 | Amarin Pharma, Inc. | $10 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-25 | Amarin Pharma, Inc. | $3 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-24 | Amarin Pharma, Inc. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-24 | Amarin Pharma, Inc. | $10 | Travel and Lodging | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-16 | Amarin Pharma, Inc. | $10 | Travel and Lodging | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-16 | Amarin Pharma, Inc. | $10 | Travel and Lodging | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-16 | Amarin Pharma, Inc. | $10 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-16 | Amarin Pharma, Inc. | $10 | Travel and Lodging | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-13 | Amarin Pharma, Inc. | $3,120 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-12 | Amarin Pharma, Inc. | $148 | Travel and Lodging | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-12 | Amarin Pharma, Inc. | $131 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-12 | Amarin Pharma, Inc. | $10 | Food and Beverage | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-11 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-03-11 | Amgen Inc. | $517 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-03-10 | Amgen Inc. | $138 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-03-10 | Amarin Pharma, Inc. | $101 | Food and Beverage | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-10 | Amarin Pharma, Inc. | $25 | Travel and Lodging | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-10 | Amarin Pharma, Inc. | $20 | Travel and Lodging | In-kind items and services | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-10 | Amgen Inc. | $15 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-03-10 | Amgen Inc. | $10 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-03-10 | Amarin Pharma, Inc. | $10 | Food and Beverage | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-09 | Amgen Inc. | $3,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-03-06 | Amarin Pharma, Inc. | $300 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-06 | Amgen Inc. | $13 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-03-06 | Amgen Inc. | $10 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-03-06 | Amarin Pharma, Inc. | $10 | Travel and Lodging | Cash or cash equivalent | Vascepa Drug, Cardiovascular | 2020 | |
| 2020-03-06 | Amgen Inc. | $10 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-03-04 | Amgen Inc. | $125 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-03-04 | Amgen Inc. | $115 | Travel and Lodging | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-03-04 | Amgen Inc. | $94 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2020 | |
| 2020-03-04 | Amgen Inc. | $25 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 | |
| 2020-03-04 | Amgen Inc. | $23 | Food and Beverage | Cash or cash equivalent | Repatha Biological, Cardiology | 2020 |
The latest 200 records of 540.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-01-02 | Amgen Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $22,762 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascu | 2025 |
| 2024-04-19 | Amgen Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $15,895 | OCEANa-Outcomes P3 CV | 2024 |
| 2024-01-16 | Amgen Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $4,406 | OCEANa-Outcomes P3 CV | 2024 |
| 2023-05-23 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $15,180 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-03-21 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,215 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-03-13 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $500 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-03-13 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $500 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2023 |
| 2023-03-07 | Amgen Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $14,763 | Phase 3 - Cardiovascular Outcomes Trial | 2023 |
| 2023-01-21 | Amgen Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $19,275 | P0 ASCVD Olpasiran Prescreening for CVOT | 2023 |
| 2022-10-18 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-09-12 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $250 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-18 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-01 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $50 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,239 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-20 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,239 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,239 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,239 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,239 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,239 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,239 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,239 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-22 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $100 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-22 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $195 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-22 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-22 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $250 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-22 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $750 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $338 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-09 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $50 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-02-18 | Amgen Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,900 | GOULD | 2022 |
| 2022-01-24 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-24 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-24 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-24 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-05 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $285 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-05 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $81 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-04 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $50 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-04 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $588 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2021-12-21 | Kowa Research Institute, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $223 | K-877-302 | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Kowa Research Institute, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,665 | K-877-302 | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | Kowa Research Institute, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $223 | K-877-302 | 2021 |
| 2021-12-01 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-10 | Kowa Research Institute, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $750 | K-877-302 | 2021 |
| 2021-10-25 | Kowa Research Institute, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $2,231 | K-877-302 | 2021 |
| 2021-10-22 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-22 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-22 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-22 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-22 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-22 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,239 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-10-22 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-09-30 | Amgen Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,325 | (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States | 2021 |
| 2021-09-27 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $500 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-09-23 | Kowa Research Institute, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $1,175 | K-877-302 | 2021 |
| 2021-08-25 | Amgen Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $3,300 | (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States | 2021 |
| 2021-08-25 | Kowa Research Institute, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $2,111 | K-877-302 | 2021 |
| 2021-08-24 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-24 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-04 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $855 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-08-04 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $900 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-27 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-27 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-27 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-27 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $196 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-07-27 | Kowa Research Institute, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $714 | K-877-302 | 2021 |
| 2021-07-20 | Esperion Therapeutics, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $750 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-06-23 | Kowa Research Institute, Inc. | SPARROW CLINICAL RESEARCH INSTITUTE | $2,007 | K-877-302 | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Lansing, MI, county Ingham County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Lansing, MI | County Ingham County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 113,023 | 283,913 | 10,077,761 |
| Population, 2020 census P1 | 112,644 | 284,900 | 10,077,331 |
| Median age B01002 | 33.7 | 33.3 | 40.2 |
| Under 18 B01001 | 21.6% | 19.6% | 21.2% |
| 65 and over B01001 | 13.6% | 14.9% | 18.6% |
| Households B11001 | 51,588 | 117,096 | 4,076,369 |
| Foreign born B05002 | 9.8% | 9.4% | 7.2% |
| Median household income B19013 | $54,382 | $65,526 | $72,875 |
| Median family income B19113 | $70,362 | $94,140 | $93,357 |
| Per capita income B19301 | $30,958 | $37,723 | $40,735 |
| Poverty rate B17001 | 20.1% | 16.7% | 13.2% |
| Unemployment rate B23025 | 8.2% | 6.2% | 5.7% |
| Civilian labor force B23025 | 62,313 | 150,853 | 5,018,449 |
| Mean commute (minutes) B08013 | 18.9 | 20.5 | 24.2 |
| Bachelor's degree or higher B15003 | 30.2% | 41.2% | 32.4% |
| Housing units B25001 | 55,943 | 126,232 | 4,622,236 |
| Owner-occupied B25003 | 53.8% | 59.5% | 73.2% |
| Renters B25003 | 46.2% | 40.5% | 26.8% |
| Median home value B25077 | $128,700 | $198,800 | $231,600 |
| Median gross rent B25064 | $993 | $1,084 | $1,129 |
| White, not Hispanic B03002 | 50.6% | 66.6% | 72.4% |
| Black B03002 | 21.9% | 11.0% | 13.1% |
| Hispanic or Latino B03002 | 12.9% | 8.7% | 5.9% |
| Asian B03002 | 5.3% | 6.2% | 3.4% |
| American Indian and Alaska Native B03002 | 0.3% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Lansing, MI.
Comments